

Illustrative anti-BCMA CARs
SP
Anti-BCMA VL
Linker
Anti-BCMA VH
Hinge CD8α
TM CD8α
4-1BB
CD3ζ
Anti-BCMA scFv
SP
Anti-BCMA VH
Linker
Anti-BCMA VL
Hinge CD8α
TM CD8α
4-1BB
CD3ζ
Anti-BCMA scFv

FIG. 1



CAR Expression (% BCMA-Fc)
0
20
40
60
80
UTD
Comparator
CAR1
CAR2
CAR3
CAR4
CAR5
CAR6

FIG. 2B



Vector Copies/Cell
0
2
4
6
UTD
Comparator
CAR1
CAR2
CAR3
CAR4
CAR5
CAR6

FIG. 2A



CAR Expression (% Fc-BCMA)
100
80
60
40
20
0
UTD
Comparator
CAR 7
CAR 8
CAR 9
CAR 10

FIG. 2D



VCN
10
8
6
4
2
0
UTD
Comparator
CAR 7
CAR 8
CAR 9
CAR 10

FIG. 2C




FIG. 3A

FIG. 3B




FIG. 3C




FIG. 3F




FIG. 3E




FIG. 3D




FIG. 3I




FIG. 3H




FIG. 3G



Antigen Dependent IL2 Release
Target: RPMI8226 (BCMA high)
IL2 (pg/mL)
4x10^3
3x10^3
2x10^3
1x10^3
0
*
*
UTD
Comparator
CAR1
CAR5
CAR9
CAR10

FIG. 3K



Antigen Dependent IL2 Release
Target: Jeko1 (BCMA low)
IL2 (pg/mL)
4x10^3
3x10^3
2x10^3
1x10^3
0
*
*
UTD
Comparator
CAR1
CAR5
CAR9
CAR10

FIG. 3J




FIG. 4C




FIG. 4B




FIG. 4A



Antigen Dependent Cytotoxicity
UTD
Comparator
CAR1
CAR5
CAR9
CAR10
Tumor Cell Count
1.5x10^5
1x10^5
5x10^4
0
0
50
100
150
200
Time Elapsed (Hours)

FIG. 5



BCMA antigen/receptor density
Receptor Density (ABC)
1000000
100000
10000
1000
100
10
1
HT.1080
RL
Toledo
Daudi
RPMI-8226
HT.1080.BCMA

FIG. 6



Antigen Dependent Proliferation
T Cell Count
8x10^4
6x10^4
4x10^4
2x10^4
0
UTD
Comparator
CAR1
CAR5
CAR9
CAR10

FIG. 7B



Antigen Independent Proliferation
T Cell Count
8x10^4
6x10^4
4x10^4
2x10^4
0
UTD
Comparator
CAR1
CAR5
CAR9
CAR10

FIG. 7A